74 related articles for article (PubMed ID: 24156249)
1. Odanacatib for the treatment of postmenopausal osteoporosis.
Chapurlat RD
Expert Opin Pharmacother; 2014 Jan; 15(1):97-102. PubMed ID: 24156249
[TBL] [Abstract][Full Text] [Related]
2. Treatment of postmenopausal osteoporosis with odanacatib.
Chapurlat RD
Expert Opin Pharmacother; 2014 Mar; 15(4):559-64. PubMed ID: 24456412
[TBL] [Abstract][Full Text] [Related]
3. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women.
Chapurlat RD
Ther Adv Musculoskelet Dis; 2015 Jun; 7(3):103-9. PubMed ID: 26029271
[TBL] [Abstract][Full Text] [Related]
4. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
[TBL] [Abstract][Full Text] [Related]
5. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
6. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Lewiecki EM
IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
[TBL] [Abstract][Full Text] [Related]
7. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
8. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
Eisman JA; Bone HG; Hosking DJ; McClung MR; Reid IR; Rizzoli R; Resch H; Verbruggen N; Hustad CM; DaSilva C; Petrovic R; Santora AC; Ince BA; Lombardi A
J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
[TBL] [Abstract][Full Text] [Related]
9. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Langdahl B; Binkley N; Bone H; Gilchrist N; Resch H; Rodriguez Portales J; Denker A; Lombardi A; Le Bailly De Tilleghem C; Dasilva C; Rosenberg E; Leung A
J Bone Miner Res; 2012 Nov; 27(11):2251-8. PubMed ID: 22777865
[TBL] [Abstract][Full Text] [Related]
10. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Watanabe R; Okazaki R
Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
[TBL] [Abstract][Full Text] [Related]
11. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.
Zanchetta JR; Bogado CE; Cisari C; Aslanidis S; Greisen H; Fox J; Lems W
Curr Med Res Opin; 2010 Nov; 26(11):2627-33. PubMed ID: 20923256
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
13. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women.
Pérez-Castrillón JL; Pinacho F; De Luis D; Lopez-Menendez M; Dueñas Laita A
J Osteoporos; 2010 Jun; 2010():. PubMed ID: 20948576
[TBL] [Abstract][Full Text] [Related]
14. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.
Zerbini CA; McClung MR
Ther Adv Musculoskelet Dis; 2013 Aug; 5(4):199-209. PubMed ID: 23904864
[TBL] [Abstract][Full Text] [Related]
15. Emerging Therapies for Osteoporosis.
McClung MR
Endocrinol Metab (Seoul); 2015 Dec; 30(4):429-35. PubMed ID: 26354487
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with odanacatib maintains normal trabecular biomechanical properties in ovariectomized adult monkeys as demonstrated by micro-CT-based finite element analysis.
Cabal A; Williams DS; Jayakar RY; Zhang J; Sardesai S; Duong LT
Bone Rep; 2017 Jun; 6():26-33. PubMed ID: 28377978
[TBL] [Abstract][Full Text] [Related]
17. Effects of bisphosphonates on matrix mineralization.
Boivin G; Meunier PJ
J Musculoskelet Neuronal Interact; 2002 Dec; 2(6):538-43. PubMed ID: 15758388
[TBL] [Abstract][Full Text] [Related]
18. [Odanacatib (MK-0822)].
Nagase Y; Tanaka S
Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
[TBL] [Abstract][Full Text] [Related]
19. New insights into treatment of osteoporosis in postmenopausal women.
Geusens P
RMD Open; 2015; 1(Suppl 1):e000051. PubMed ID: 26557374
[TBL] [Abstract][Full Text] [Related]
20. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
